original ) (raw )Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial
Fedro Peccatori
2002
View PDFchevron_right
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12–93
Olivia Pagani
Breast Cancer Research and Treatment, 2009
View PDFchevron_right
Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy
Tadahiko Shien
The Breast, 2007
View PDFchevron_right
Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer
Vladimir Semiglazov , Garik Dashyan
Cancer, 2007
View PDFchevron_right
Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer
Noriyuki Katsumata
British journal of cancer, 2009
View PDFchevron_right
Predictors of response to second-line endocrine therapy for breast cancer
Sarah Pinder
Breast Cancer Research and Treatment, 1997
View PDFchevron_right
Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer
Marc Lippman
European Journal of Cancer (1965), 1980
View PDFchevron_right
The sequential use of endocrine treatment for advanced breast cancer: where are we?
M. Gnant
Annals of Oncology, 2012
View PDFchevron_right
Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself
Lissandra Lago
International Journal of Gynecological Cancer, 2006
View PDFchevron_right
High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy
Per Lønning
Breast Cancer Research and Treatment, 2001
View PDFchevron_right
Challenges in the endocrine management of breast cancer
Carsten Rose
The Breast, 2003
View PDFchevron_right
The evolving role of endocrine therapy for early stage breast cancer
Jennifer Manders
Breast Cancer, 2005
View PDFchevron_right
Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: Still a question?
A. Goldhirsch , Alan Coates
Cancer Treatment Reviews, 1998
View PDFchevron_right
The definition of the ‘no change’ category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast
Mary Jones
European Journal of Cancer and Clinical Oncology, 1988
View PDFchevron_right
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
Olivia Pagani
Annals of Oncology, 2008
View PDFchevron_right
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93
John Forbes , A. Goldhirsch , Alan Coates
Breast Cancer Research and Treatment, 2009
View PDFchevron_right
Endocrine Factors in the Outcome of Systemic Adjuvant Therapy of Early Breast Cancer
alfredo marinelli
Annals of The New York Academy of Sciences, 1993
View PDFchevron_right
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer
Sara Bravaccini
Medicine, 2020
View PDFchevron_right
Endocrine Therapy in Metastatic Breast Cancer
rosalba amodio
Annals of the New York Academy of Sciences, 2009
View PDFchevron_right
Extended Adjuvant Endocrine Therapy in Breast Cancer: Current Status and Future Directions
Marcel Jinih
Clinical Cancer Updates, 2008
View PDFchevron_right
Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Jean-Louis Achard
The Oncologist, 2007
View PDFchevron_right
Endocrine therapy for breast cancer
C. Heldermon
Update on Cancer Therapeutics, 2006
View PDFchevron_right